February 12, 2015 | The Israeli biomedical company RedHill Biopharma raised $12.5 million in its initial public offering on NASDAQ. The offering was led by Wells Fargo Securities along with Roth Capital Partners and MLV & Co. The offering price ran at $12.5 per share for each American Depository Share, which represents ten ordinary shares. RedHill specializes in the development of drug delivery methods as well as combinations of existing drug-types. The company’s most popular drug types are for the treatment of Chrohn’s disease and for the nausea associated with chemotherapy.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments